Tocris Introduces New Fluorescent Dyes Range

Tocris Bioscience, part of the Biotechnology division of Bio-Techne, has released a new range of fluorescent dyes, known as Janelia Fluor™ dyes, for advanced imaging techniques. The molecules were developed by Luke Lavis' lab at the Janelia Research Campus and have been licensed to Tocris by the Howard Hughes Medical Institute (HHMI).

The range comprises Janelia Fluor™ dyes JF₆₄₆ and JF₅₄₉ and photoactivatable derivatives of these reagents. The new dyes are rhodamine-based and are brighter and more photostable than currently available tetramethylrhodamine (TMR) dyes. They are also cell-permeable and are supplied as NHS esters for ease of conjugation to antibodies and other proteins. To date Janelia Fluor™ dyes have been used in super resolution microscopy, including dSTORM, single molecule tracking in cells, confocal fluorescent imaging and are also suitable for multiplexing. Tocris Product Manager, Dr Hannah Maple said, "We are excited to make these innovative new dyes commercially available to the research community. They are widely applicable across a range of advanced imaging techniques and should enable life science researchers to generate enhanced images and accelerate new discoveries."

For more information on Janelia Fluor™ dyes see, www.tocris.com/fluorescent-dyes

About Tocris Bioscience

Bristol-based Tocris Bioscience is part of the Biotechnology division of Bio-Techne. Our goal is to provide the global life science research community with the most innovative and high performing products to enable ground breaking discoveries. From its origins as a supplier of neuroscience research products, Tocris Bioscience has expanded to now offer innovative chemical tools for research in fields such as cancer, epigenetics and stem cells.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. Bio-Techne has approximately 1,650 employees worldwide and generated approximately $499 million in net sales in fiscal 2016. For more information on Bio-Techne and its brands, please visit bio-techne.com.